Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2520-2520
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential
Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111278-111278
Closed Access | Times Cited: 1
Cardiovascular safety of psychedelic medicine: current status and future directions
Agnieszka Wsół
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1362-1380
Open Access | Times Cited: 20
Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial
Ellen James, David Erritzøe, Tiffanie Benway, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
Low-carbohydrate diet as a nutritional intervention in a major depression disorder: focus on relapse prevention
Michał Walaszek, Zofia Kachlik, Wiesław Jerzy Cubała
Nutritional Neuroscience (2024), pp. 1-14
Closed Access | Times Cited: 6
Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022
Mark Simon, Heather Olsen, Christopher Hoyte, et al.
Annals of Emergency Medicine (2024) Vol. 84, Iss. 6, pp. 605-618
Closed Access | Times Cited: 4
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials
Aleksander Kwaśny, Alina Wilkowska, Wiesław Jerzy Cubała
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
Psychedelics as moral bioenhancers: Protocol for a scoping review of ethical arguments for and against
S L Streicher, Christopher Register, Xiu Lim, et al.
Wellcome Open Research (2025) Vol. 10, pp. 3-3
Open Access
Exploring the Role of Psychedelic Experiences on Wellbeing and Symptoms of Disordered Eating
Nadine Loh, David Luke
Psychoactives (2025) Vol. 4, Iss. 1, pp. 7-7
Open Access
Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy
Erika Belitzky, Leonardo César Carvalho, Melissa V. Taylor, et al.
Cancer Medicine (2025) Vol. 14, Iss. 5
Open Access
A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress
Fejzic Dino
Cureus (2025)
Open Access
Peak Experiences Matter
Danielle Leonard, Thomas R. Brooks
Journal of Humanistic Psychology (2025)
Closed Access
The Pharmacological Treatment of Anxiety in People with Eating Disorders: A Systematic Review
R. Crawford Morris, Johanna Louise Keeler, Janet Treasure, et al.
Pharmacological Research (2025), pp. 107782-107782
Open Access
Trainees Unprepared for Advances in Psychedelic Medicine: A Survey Study
Jamarie Geller, Nicolas G. Glynos, Andrew Lemmen, et al.
Journal of Psychoactive Drugs (2024), pp. 1-8
Closed Access | Times Cited: 3
Unraveling the metabolomic profile and acute toxicity of ethanolic extract from Mimosa tenuiflora (Willd.) Poir. root bark
Renato Pinto de Sousa, Carlos Mario Freitas de Oliveira, Rita de Cassia de Lima Sousa, et al.
Toxicon (2024) Vol. 249, pp. 108076-108076
Closed Access | Times Cited: 2
Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies
Stephanie L. Borgland, Drew M. Neyens
Journal of Psychiatry and Neuroscience (2022) Vol. 47, Iss. 3, pp. E218-E221
Open Access | Times Cited: 11
Alkaloids from the entheogenic plant Peganum harmala
Daniel G. Anstis, Jessica Liyu, Emma K. Davison, et al.
Australian Journal of Chemistry (2023) Vol. 76, Iss. 5, pp. 264-278
Closed Access | Times Cited: 5
Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use
Kiffer G. Card, Ashmita Grewal, Kalysha Closson, et al.
Journal of Psychoactive Drugs (2023), pp. 1-11
Closed Access | Times Cited: 5
Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential
P. Deepak Raj, Shyambabu Rauniyar, Bhagyesh Sapkale
Cureus (2023)
Open Access | Times Cited: 4
Behavior, antioxidant, and metabolomics effects of Allium tuncelianum
Nigar Abbak, Emirhan Nemutlu, Tuba Reçber, et al.
Food Science & Nutrition (2024) Vol. 12, Iss. 5, pp. 3538-3551
Open Access | Times Cited: 1
Effectiveness of a phone-based support program on self-care self-efficacy, psychological distress, and quality of life among women newly diagnosed with breast cancer: A randomized controlled trial
Xijing Chen, Yang Qin, Nujjaree Chaimongkol
European Journal of Oncology Nursing (2024) Vol. 71, pp. 102643-102643
Closed Access | Times Cited: 1
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
Giuseppe Pasculli, Pierpaolo Busan, Eric S. Jackson, et al.
Frontiers in Human Neuroscience (2024) Vol. 18
Open Access | Times Cited: 1
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Claire Miller, Phillip R. Zoladz
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 392, Iss. 1, pp. 100026-100026
Closed Access | Times Cited: 1
Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases
Izabela Szpręgiel, Izabela Szpręgiel
Pharmacological Reports (2024) Vol. 76, Iss. 6, pp. 1297-1304
Open Access | Times Cited: 1
Production, Characterization, and In Vitro and In Vivo Studies of Nanoemulsions Containing St. John’s Wort Plant Constituents and Their Potential for the Treatment of Depression
Ahmad Salawi, Yosif Almoshari, Muhammad H. Sultan, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 490-490
Open Access | Times Cited: 2
Synthetic studies toward the marine alkaloid convolutindole A, a structurally remarkable derivative of the hallucinogen N,N-Dimethyltryptamine (DMT)
Karen Ichikawa, Jessica C. Neville, Yihan Yu, et al.
Tetrahedron Letters (2023) Vol. 129, pp. 154756-154756
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top